Biological
SVN53-67/M57-KLH peptide vaccine clinical trials
Also written SurVaxM.
Keep track of what changes. Save the SVN53-67/M57-KLH peptide vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 6
Roswell Park Cancer Institute (4) · MimiVax, LLC (1) · David Peereboom (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Temozolomide (2) · Lenalidomide (1) · Incomplete Freund's adjuvant (1) · Octreotide (1) · Sargramostim (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses SVN53-67/M57-KLH peptide vaccine is read from its arms, and is right about nine times in ten.
Testing it · 7
- Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasNot yet recruitingPhase 2Roswell Park Cancer InstituteNCT06202066Written as SVN53-67/M57-KLH Peptide Vaccine
- Testing the SurVaxM Vaccine for Lung Cancer PreventionNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07169617Written as SVN53-67/M57-KLH Peptide Vaccine
- SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingPhase 2Roswell Park Cancer InstituteNCT02455557Written as SVN53-67/M57-KLH Peptide Vaccine
- SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance TherapyActive, not recruitingPhase 1Roswell Park Cancer InstituteNCT02334865Written as SVN53-67/M57-KLH Peptide Vaccine
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsCompletedPhase 1Roswell Park Cancer InstituteNCT03879694Written as SVN53-67/M57-KLH Peptide Vaccine
- Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First RecurrenceCompletedPhase 2David PeereboomNCT04013672Written as SurVaxM
- SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)Active, not recruitingPhase 2MimiVax, LLCNCT05163080Written as SurVaxM
Codes
What other systems call SVN53-67/M57-KLH peptide vaccine · ClinicalTrials.gg INT016781
- UNII (FDA) HK7BJ56KSPSVN53-67/M57-KLH PEPTIDE VACCINEOne source FDA
- NCI Thesaurus C95705SVN53-67/M57-KLH Peptide VaccineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HK7BJ56KSP | SVN53-67/M57-KLH PEPTIDE VACCINE | One source FDA |
| NCI Thesaurus | C95705 | SVN53-67/M57-KLH Peptide Vaccine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.